Long-term prognostic factors for PRRT in neuroendocrine tumors

Long-term prognostic factors for PRRT in neuroendocrine tumors

Aim/introductionPeptide receptor radionuclide therapy (PRRT) is an effective and well-tolerated treatment option for patients with neuroendocrine tumors (NETs) that prolongs progression-free survival (PFS). However, the limited overall survival (OS) rates in the prospective phase III study (NETTER1)...

Full description

Bibliographic Details
Main Authors: Nils Florian Trautwein, Johannes Schwenck, Johann Jacoby, Gerald Reischl, Francesco Fiz, Lars Zender, Helmut Dittmann, Martina Hinterleitner, Christian la Fougère
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-06-01
Series:Frontiers in Medicine
Subjects:
neuroendocrine tumor (NET)
177Lu
DOTA-TATE
peptide receptor radionuclide therapy (PRRT)
Ga-HA-DOTATATE
molecular tumor volume
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1169970/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1169970/full

Similar Items